Great Britain versus Northern Ireland: Two Regulatory Tracks

1. Key takeaways

Medical device regulation in the United Kingdom runs on two tracks that cannot substitute for one another: Great Britain (England, Wales and Scotland) applies the UK MDR 2002, while Northern Ireland applies Regulation (EU) 2017/745 (the EU MDR) and Regulation (EU) 2017/746 (the EU IVDR) under the Windsor Framework, with the MHRA acting as the competent authority for Northern Ireland. A company supplying both regions is therefore operating two parallel compliance procedures at the same time — separate registration routes, separate representative arrangements and separate marking logic. Since 28 May 2026, the registration obligation for non-custom-made devices in Northern Ireland has shifted further, moving from the MHRA to EUDAMED. The practical consequence is that territory allocation is no longer a logistics question but a regulatory one: where a device is sold determines which legal regime, which registration system and which representative obligations apply to it.

2. Legal basis

The dual-track structure rests on both domestic and European instruments, which must be consulted together:

• UK MDR 2002 (SI 2002/618, as amended): regulation 2A (qualifying Northern Ireland goods), regulation 3ZA, regulation 4T, regulations 10A / 24A / 36A (the UK(NI) indication), and regulations 4O and 4P (disapplying Regulation (EU) 2017/745 and Regulation (EU) 2017/746 in United Kingdom law).
• The Medical Devices (Northern Ireland Protocol) Regulations 2021 (SI 2021/905): made on 26 July 2021, in force from 27 July 2021; regulation 2 (scope), regulation 10 (the UK(NI) indication under the EU MDR), regulation 10C (the UK(NI) indication under the EU IVDR).
• Regulation (EU) 2017/745 and Regulation (EU) 2017/746: dated 5 April 2017.
• Official guidance: the GOV.UK page Register medical devices to place on the market (Northern Ireland registration section, stating that registration in EUDAMED is required from 28 May 2026).

The pairing matters because each track borrows language from the other: the domestic regulation defines where Northern Ireland stands, while SI 2021/905 carries the European obligations into United Kingdom law for that territory. Reading either instrument alone gives only half of the picture.

3. Expert insights

Insight 1: the geographic boundary is not the legal boundary. A company that establishes one warehouse in the United Kingdom and signs one distribution agreement, without expressly limiting the territory to Great Britain, may find its goods flowing into Northern Ireland — at which point EU MDR/IVDR obligations attach, including an EU authorised representative, CE marking and EUDAMED registration. This is the most common over-scope violation in the United Kingdom market, and it arises not from deliberate non-compliance but from contracts and logistics documents that never addressed the boundary at all. Fixing it requires reviewing the commercial paper, not just the technical file.

Insight 2: registration in Northern Ireland is now split by device category. From 28 May 2026, non-custom-made devices must be registered in EUDAMED before being placed on the European Union and Northern Ireland markets, and MHRA registration is no longer required for them; custom-made devices fall outside the scope of EUDAMED and must still be registered with the MHRA within 28 days of being placed on the Northern Ireland market (SI 2021/905, regulation 7(2)(a)). The registration obligations of the two categories are now fully separated, and applying one category’s rule to the other produces either an unlawful gap or unnecessary duplicate filing.

Insight 3: a Great Britain manufacturer is an outside entity in Northern Ireland. Under the official guidance, manufacturers established in Great Britain placing devices on the Northern Ireland market must still appoint an authorised representative established in the European Union or in Northern Ireland. This point is frequently misunderstood as meaning that no authorised representative is needed inside the United Kingdom for internal trade. The misunderstanding is costly: it surfaces late, usually when a distributor or competent authority asks for the representative details on the label or in the declaration of conformity.

4. Practical recommendations

GRZAN recommends recording the target territory explicitly in sales contracts and logistics documents, and separating the compliance status of Great Britain and Northern Ireland as distinct fields in product master data. For product lines covering both regions, maintain a dual ledger: one column tracking the UKRP and MHRA registration position under the UK MDR 2002, the other tracking the authorised representative and EUDAMED position under the EU MDR/IVDR. Reconcile the two columns whenever either side changes — a certificate renewal, a representative appointment, a territory adjustment — rather than only at annual review, because the two tracks move on different calendars and a single-track change can silently invalidate the other side’s assumptions.

5. Verification checklist

• □ The target territory (Great Britain, Northern Ireland, or both) has been distinguished
• □ Non-custom-made devices for Northern Ireland have completed EUDAMED registration
• □ MHRA registration within 28 days of placing on the Northern Ireland market has been planned for custom-made devices
• □ A Great Britain manufacturer involved in Northern Ireland has appointed an authorised representative established in the European Union or Northern Ireland
• □ Contracts and logistics documents have been annotated with territory restrictions

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers with the following services for the United Kingdom market:

• Appointment of the UK Responsible Person (UKRP) and signature support for the letter of authorisation
• End-to-end MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee estimation
• Dual-track design for Great Britain and Northern Ireland, including UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance report submission
• Emergency response to serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

GRZAN provides end-to-end MHRA registration and compliance support for manufacturers entering the United Kingdom market, covering every stage from market entry planning through post-market obligations. For enquiries, contact info@grzanglobal.com.